Press Release: EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor

“EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor. Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the European Medicines Agency (EMA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria.” To read entire press release: www.prlog.org

The release as fetched from its publisher. amyndas.com ↗